Biogen’s investigational treatment Aducanumab for early Alzheimer’s disease (AD) has secured fast-track designation from the US Food and Drug Administration (FDA).

The programme will support the development of new treatments for serious conditions with an unmet medical need such as Alzheimer’s.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Biogen executive vice-president and chief medical officer Alfred Sandrock said: “By collaborating with regulators through programmes such as Fast Track, we hope to bring effective treatments to patients and families affected by Alzheimer’s disease (AD) as quickly as possible.”

At present, the treatment is being evaluated in two global Phase III studies, Engage and Emerge, which are designed to evaluate its safety in slowing cognitive impairment and the progression of disability in people with this disease.

" … We hope to bring effective treatments to patients and families affected by Alzheimer’s disease (AD) as quickly as possible."

The ongoing Phase Ib randomised, double-blind, placebo-controlled, multiple-dose Prime study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects of aducanumab in patients with prodromal or mild AD.

Aducanumab (BIIB037) is an investigational compound being developed to treat early AD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This human-recombinant monoclonal antibody (mAb) is believed to target aggregated forms of beta amyloid, including soluble oligomers and insoluble fibrils deposited into the amyloid plaque in the brain of AD patients.

AD is a progressive neurodegenerative disorder characterised by cognitive decline and behavioural disturbances that ultimately result in a person’s inability to perform daily activities.